Phase 1/2 Trials

Zigakibart sustains proteinuria remission and stabilizes kidney function over 100-week IgA nephropathy trial

Phase 1/2 results position APRIL pathway blockade as a key driver of pathogenic IgA1 reduction with a global Phase 3 trial underway.